David M. Rubitski
Pfizer (United States)(US)
Publications by Year
Research Areas
Virus-based gene therapy research, CRISPR and Genetic Engineering, Viral Infectious Diseases and Gene Expression in Insects, Cholinesterase and Neurodegenerative Diseases, Neurotransmitter Receptor Influence on Behavior
Most-Cited Works
- → Selective Inhibition of Casein Kinase 1ϵ Minimally Alters Circadian Clock Period(2009)179 cited
- → Receptor-Mediated Delivery of CRISPR-Cas9 Endonuclease for Cell-Type-Specific Gene Editing(2018)153 cited
- → Discovery of Two Clinical Histamine H 3 Receptor Antagonists: trans - N -Ethyl-3-fluoro-3-[3-fluoro-4-(pyrrolidinylmethyl)phenyl]cyclobutanecarboxamide (PF-03654746) and trans -3-Fluoro-3-[3-fluoro-4-(pyrrolidin-1-ylmethyl)phenyl]- N -(2-methylpropyl)cyclobutanecarboxamide (PF-03654764)(2011)107 cited
- → The 5-Hydroxytryptamine4 Receptor Agonists Prucalopride and PRX-03140 Increase Acetylcholine and Histamine Levels in the Rat Prefrontal Cortex and the Power of Stimulated Hippocampal θ Oscillations(2012)57 cited
- → Identification of Multiple 5-HT4Partial Agonist Clinical Candidates for the Treatment of Alzheimer’s Disease(2012)42 cited
- → Identification of Phosphorylation Consensus Sequences and Endogenous Neuronal Substrates of the Psychiatric Risk Kinase TNIK(2015)38 cited
- → Casein Kinase 1δ/ε Inhibitor PF-5006739 Attenuates Opioid Drug-Seeking Behavior(2014)36 cited
- → Comparing molecular and computational approaches for detecting viral integration of AAV gene therapy constructs(2023)19 cited
- → In vitro NIH3T3 mouse embryonic fibroblast cell model does not predict AAV2 or AAVdj-mediated cell transformation(2025)2 cited
- → Comparison and cross-validation of long-read and short-read target-enrichment sequencing methods to assess AAV vector integration into host genome(2024)1 cited